Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 821 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... May 7, 2021 Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... June 22, 2026 Load more HOT NEWS FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include... Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal... Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... The 10-year cancer plan: is improving cancer survival still a priority...
